A Novel Role for Raloxifene Nanomicelles in Management of Castrate Resistant Prostate Cancer
Figure 2
Comparison of the effect of various concentrations of raloxifene (Ral) and SMA-Ral (SMA-Ral) on the proliferation of PC3 (a) and DU145 (b) cells. Cells were treated over a period of 72 h with specific concentrations of raloxifene or SMA-Ral. At the indicated time point, cells were fixed and cell number was determined using the sulforhodamine B assay. Data are expressed as mean ± SEM ().
